NSE filing, NSE: NIVABUPA. Summary written from the filing by ALFA Finder's alert engine.
Niva Bupa Health Insurance Company Ltd: key numbers
- Share price
- ₹72.78
- Market cap
- ₹13,462 Cr
- Revenue (annual)
- ₹6,695 Cr
- Net profit (annual)
- ₹130.8 Cr
- P/E (TTM)
- 37.4×Sector 19.7×
- Promoter holding
- 55.29%-0.01% QoQ
- FII holding
- 12.95%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Niva Bupa Health Insurance Company Ltd
All →Niva Bupa Health Insurance Company Board Meeting Date
Niva Bupa will hold a board meeting on November 4, 2026 to consider unaudited results for the quarter and half-year ended September 30, 2026. The trading window stays closed until November 6, 2026.
Niva Bupa Health Insurance Company Management Change
Niva Bupa Health Insurance Company Limited announced the sad demise of Mr. Roger William John Davis, a Non-Executive Non-Independent Director, effective October 17, 2026.
Niva Bupa Health Insurance Company Other Announcement
Niva Bupa Health Insurance announced the sad demise of Non-Executive Director Mr. Roger William John Davis, effective October 17, 2026.
Niva Bupa Health Insurance Company Credit Rating
Niva Bupa Health Insurance received a credit rating of IND AAA/Stable for its proposed subordinated debt issuance. This rating reflects the company's proposed debt instrument.
Niva Bupa Health Insurance Company Debt & Borrowing: ₹150 Cr
Niva Bupa Health Insurance will exercise its call option to redeem 1,500 non-convertible debentures on November 15, 2026, for a total principal amount of ₹150 Crore.
- Value
- ₹150.0 Cr
Niva Bupa Health Insurance Company Board Meeting Date
Niva Bupa Health Insurance will hold a committee meeting on 09-Oct-2026 to consider altering the payment date for interest or redemption amounts on debt securities.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.